FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is scheduled to begin operations this year.

Biotechs (Regeneron and Amgen) also played a key role here. Ferguson looks for solid cash flows and strong balance sheets and likes to scoop up biotechs after their share prices decline.

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.